Align Know-how’s board of administrators has licensed a brand new inventory repurchase program price US$1 billion, following the completion of its earlier US$1-billion buyback on Could 1.
The brand new program permits Align to repurchase as much as US$1 billion of its frequent inventory over the following three years. The prior authorization, authorized in January 2023, was accomplished on Could 1, 2025, with settlement on Could 2.
The announcement follows the discharge of Align’s first-quarter 2025 monetary outcomes on April 30, which confirmed a slight decline in whole income however beat earnings expectations. In April, Morgan Stanley additionally decreased Align’s worth goal from US$272 to US$249 however maintained its “obese” ranking, indicating continued confidence within the firm’s potential.
“The brand new US$1-billion program displays the energy of our steadiness sheet and money stream technology.” John Morici, Align’s CFO and government vice-president, international finance.
“The brand new US$1-billion program displays the energy of our steadiness sheet and money stream technology, in addition to administration’s and our board’s continued confidence in our capacity to capitalize on giant market alternatives in our goal markets and trajectory for progress,” mentioned John Morici, Align’s CFO and government vice-president, international finance. “Returning capital to our shareholders via inventory repurchase applications, whereas concurrently investing in our strategic progress drivers, is according to our capital allocation technique and dedication to growing shareholder worth.”
As of March 31, Align had roughly 73.1 million shares excellent and US$873 million in money and money equivalents.
Additionally learn: Dental shares downgraded? Right here is all the things you’ll want to know as a dentist
Additionally learn: Stats Canada: Dental sector surpasses pre-pandemic productiveness ranges by $851 million as job progress rebounds
Q1 report
In late April, the corporate reported Q1 revenues of US$979.3 million, marking a 1.8 per cent lower year-over-year. Nonetheless, Clear Aligner quantity elevated by 6.2 per cent to 642,300 instances, with remedies for teenagers and rising sufferers rising 13.3 per cent to 225,800 instances, pushed by continued adoption of Invisalign First.
Regardless of headwinds from unfavourable overseas trade, Align reported a non-GAAP diluted earnings per share of US$2.13 in Q1 2025, surpassing the US$2.00 analysts’ forecast and demonstrating operational resilience.
For the second quarter, Align expects worldwide revenues to vary from US$1.05 billion to US$1.07 billion, up from Q1.
“We’ve assessed the potential influence of China’s retaliatory tariffs and consider that we’re capable of mitigate a lot of the tariff.” Align’s assertion.
Tariff outlook stays unsure
Align additionally addressed potential tariff impacts in its earnings launch. The corporate mentioned it expects an “incremental tariff, if applied, to be utilized to switch costs on items shipped from Mexico.”
“As famous in President Trump’s government order dated April 2, 2025, USMCA-compliant items are exempt from the tariffs below the order. Nonetheless, the U.S.-Mexico tariff scenario stays fluid, and we’re unable to foretell whether or not USMCA-compliant merchandise will stay exempt, whether or not there might be different modifications to the introduced order, or if extra tariffs might be imposed sooner or later,” the corporate mentioned.
Align added it doesn’t anticipate vital tariff impacts on its operations in China, the place Clear Aligners are made for the Asian market.
“We’ve assessed the potential influence of China’s retaliatory tariffs and consider that we’re capable of mitigate a lot of the tariff publicity via changes in our provide chain,” it mentioned.